Washington’s biotech market is far from frothy, but industry observers say there are a few trends to watch.
When Alpine Immune Sciences announced it had gotten $48 million from health care investment firms earlier this week, it was following a national trend of companies seeking strategic investors.
There is “more of a push for companies to look at strategic investors,” or those who can provide both money and business advice, said Life Science Washington’s Yesenia Green, who specializes in commercializing biotechnologies.
